Atezolizumab Injection
Atezolizumab Injection (Tecentriq) is an intravenous immunotherapy used to treat certain lung cancers, liver cancer, melanoma, alveolar soft part sarcoma and muscle invasive bladder cancer.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Atezolizumab (Tecentriq) is an immunotherapy given into a vein for certain lung, liver and bladder cancers, melanoma and a rare sarcoma, working by blocking PD-L1, a protein tumors use to switch off immune T cells; on the market since about 2016 and still brand-only, it is an established option used alone or alongside other cancer drugs. On its own it is usually gentler than chemotherapy, with tiredness, poor appetite, nausea, cough and itching the usual complaints. The main risk is the immune system attacking healthy organs (lungs, bowel, liver, hormone glands, skin), which can be severe or fatal, so report a new cough, breathlessness, ongoing diarrhea or blistering rash quickly.
Clinical pearls
- Immune side effects can appear even after treatment has ended, so tell any doctor or urgent care team you have had Tecentriq.
- Keep every infusion and blood test appointment, since liver enzymes, creatinine (a kidney marker) and thyroid levels are checked throughout.
- Tell your oncologist if you have ever had radiation to the chest, since lung inflammation is more common afterward.
- Use effective birth control and avoid breastfeeding during treatment and for at least 5 months after the last dose.
Patient information guide A plain-language walkthrough of Atezolizumab Injection, written from its FDA label.
What Atezolizumab Injection is used for
▾
Tecentriq (atezolizumab) is used for these cancers:
- Non-small cell lung cancer (NSCLC): after surgery and chemotherapy for stage II to IIIA with PD-L1 on at least 1% of tumor cells. Also first-line for metastatic NSCLC with high PD-L1 and no EGFR or ALK changes, with other drugs for metastatic non-squamous NSCLC, and after progression on platinum chemotherapy.
- Small cell lung cancer: first-line for extensive-stage disease with carboplatin and etoposide. Also maintenance with lurbinectedin.
- Hepatocellular carcinoma: with bevacizumab for unresectable or metastatic disease with no prior systemic therapy.
- Melanoma: with cobimetinib and vemurafenib for BRAF V600 mutation-positive unresectable or metastatic disease.
- Alveolar soft part sarcoma: for unresectable or metastatic disease in adults and children 2 and older.
- Muscle invasive bladder cancer: after cystectomy in adults with ctDNA molecular residual disease.
How Atezolizumab Injection works
▾
Tumors can display a protein called PD-L1 that signals T cells (immune cells) to stand down. Tecentriq is a monoclonal antibody that binds PD-L1 and blocks its link to the PD-1 and B7.1 receptors. This releases the brake on the immune response and helps it act against the tumor.
Atezolizumab Injection dosage
▾
Tecentriq is given by IV infusion in a clinic or hospital, never as a pill. The first infusion runs about 60 minutes, and later ones may be about 30 minutes if tolerated.
- It is given every 2, 3 or 4 weeks, depending on the plan.
- Treatment lasts up to one year for some uses and until the cancer progresses or side effects become unacceptable for others.
- Food does not apply, since it is given into a vein.
- If you miss an appointment, contact your care team to reschedule.
Dosing details from the FDA-approved label
From the Atezolizumab Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Metastatic NSCLC
- 840 mg every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks, administered intravenously over 60 minutes
- If the first infusion is tolerated, subsequent infusions may be delivered over 30 minutes
- Until disease progression or unacceptable toxicity; when given with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day
- Adjuvant treatment of NSCLC
- 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks, following resection and up to 4 cycles of platinum-based chemotherapy
- Up to one year, unless there is disease recurrence or unacceptable toxicity
- Small Cell Lung Cancer (SCLC)
- 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
- Administer TECENTRIQ prior to chemotherapy when given on the same day; until disease progression or unacceptable toxicity
- Hepatocellular Carcinoma (HCC)
- 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
- Bevacizumab is administered at 15 mg/kg every 3 weeks
- Administer TECENTRIQ prior to bevacizumab when given on the same day
- Melanoma
- 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on/7 days off) and vemurafenib 720 mg orally twice daily
- Following completion of a 28-day cycle of cobimetinib and vemurafenib (vemurafenib 960 mg twice daily Days 1-21, 720 mg twice daily Days 22-28)
- ASPS (adults)
- 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
- Until disease progression or unacceptable toxicity
- ASPS (pediatric patients 2 years of age and older)
- 15 mg/kg every 3 weeks
- Maximum: 1200 mg
- MIBC
- 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks, after cystectomy
- Up to one year, unless there is disease recurrence or unacceptable toxicity
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. NSCLC In the adjuvant setting, administer TECENTRIQ following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year. ( 2.2 ) In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. ( 2.2 ) When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day. ( 2.2 ) Small Cell Lung Cancer Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to chemotherapy when given on the same day. ( 2.2 ) Hepatocellular Carcinoma Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every 3 weeks. ( 2.2 ) Melanoma Following completion of a 28-day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily. ( 2.2 ) ASPS Adults: Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. ( 2.2 ) Pediatric patients 2 years of age and older: 15 mg/kg (up to a maximum of 1200 mg), every 3 weeks ( 2.2 ) MIBC Administer TECENTRIQ after cystectomy as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks for up to 1 year. ( 2.2 ) 2.1 Patient Selection for Treatment of Non-Small Cell Lung Cancer, Melanoma, and Muscle Invasive Bladder Cancer Select patients with Stage II to IIIA non-small cell lung cancer for treatment with TECENTRIQ as a single agent based on PD-L1 expression on tumor cells [see Clinical Studies (14.1) ]. Select patients with first-line metastatic non-small cell lung cancer for treatment with TECENTRIQ as a single agent based on the PD-L1 expression on tumor cells or on tumor-infiltrating immune cells [see Clinical Studies (14.1) ].
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Atezolizumab Injection side effects
▾
Common side effects seen with Tecentriq include:
Common side effects
- Fatigue or weakness
- Decreased appetite
- Nausea
- Cough
- Shortness of breath
- Hair loss (when given with other cancer drugs)
- Constipation or diarrhea (when given with other cancer drugs)
- Rash, itching or joint and muscle pain
- High blood pressure and protein in urine (with bevacizumab for liver cancer)
When to get medical help
- Call your care team right away for new or worsening cough, chest pain or shortness of breath, which can signal lung inflammation (pneumonitis).
- Report severe or ongoing diarrhea, or belly pain, which can signal colitis (bowel inflammation).
- Report symptoms of liver, kidney, thyroid or other hormone problems. Blood tests are checked before and during treatment.
- Report a new or severe skin rash or blistering right away.
- Tell staff right away about fever, chills, flushing or trouble breathing during an infusion.
- Immune side effects can be severe or fatal and can happen at any time, even after treatment ends.
Seek help quickly for breathing problems, severe diarrhea, severe rash, yellowing of skin or eyes, or infusion reactions.
Atezolizumab Injection warnings and precautions
▾
- Immune-mediated reactions can be severe or fatal. They can affect lungs, bowel, liver, hormone glands, skin and kidneys, and can occur after treatment ends.
- Lab tests for liver, kidney and thyroid are done before and during treatment.
- Infusion reactions may need slowing, pausing or stopping the infusion.
- Donor stem cell transplant: fatal and serious complications can occur.
- Pregnancy: can cause fetal harm.
Atezolizumab Injection interactions
▾
The label focuses on combinations used together by design.
- Bevacizumab, chemotherapy (carboplatin, paclitaxel, etoposide), lurbinectedin, cobimetinib and vemurafenib are used in specific cancers. Your oncology team manages these.
- Allogeneic stem cell transplant: serious complications are possible with PD-1/PD-L1 blockers.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Atezolizumab Injection
▾
- No contraindications are listed.
- Tell your doctor if you are pregnant, planning pregnancy or breastfeeding.
- Use effective birth control during treatment and for at least 5 months after the last dose.
- Do not breastfeed during treatment and for at least 5 months after the last dose.
- Tell your doctor about prior chest radiation and any transplant history.
- Children 2 and older are covered only for alveolar soft part sarcoma.
What Atezolizumab Injection does in the body
▾
The relationship between drug levels and the safety and effectiveness of atezolizumab, and the time course of its effects, has not been fully characterized.
How your body processes Atezolizumab Injection
▾
Atezolizumab levels rise in proportion to the dose. Steady state is reached after about 6 to 9 weeks of repeated dosing. Its terminal half-life is about 27 days, which is why it can be given every few weeks. Age, body weight, sex, race, and mild or moderate kidney or liver impairment had no clinically significant effect on exposure.
How to store Atezolizumab Injection
▾
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Atezolizumab Injection
54 supplements and herbal products have documented interactions with Atezolizumab Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Moderate · 52
- Minor · 2
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Atezolizumab Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Atezolizumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Tecentriq used for?
▾
How will I get it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Will I need blood tests?
▾
Is Atezolizumab Injection available over the counter?
▾
When was Atezolizumab Injection first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Atezolizumab Injection on HelloPharmacist
Atezolizumab Injection forms and strengths (how it comes)
Atezolizumab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Atezolizumab Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Tecentriq is used for certain NSCLC, ES-SCLC, liver cancer, melanoma, ASPS and MIBC settings.
- Tecentriq may be given alone or with other cancer medicines, depending on the cancer.
- Tecentriq is given as an intravenous infusion, first over about 60 minutes.
- Tecentriq later infusions may be shortened to about 30 minutes if the first is tolerated.
- Tecentriq is given before chemotherapy or bevacizumab when given on the same day.
Atezolizumab Injection on the U.S. market: products, makers and brands
How Atezolizumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Atezolizumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2016. Brand names on the directory include Tecentriq; the rest are generics.
How widely Atezolizumab Injection is used (Medicaid data)
A general measure of how commonly Atezolizumab Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Atezolizumab Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Atezolizumab Injection prescribed? Of the 1,601 medications we measure, Atezolizumab Injection ranks #962 by Medicaid prescriptions — more than 40% of them.
Utilization by Atezolizumab Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
20 ML atezolizumab 60 MG/ML Injection Most dispensed
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1792780
14 ML atezolizumab 60 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2119695
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Atezolizumab Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 3 listed Atezolizumab Injection NDCs with Medicaid activity.
Compare Atezolizumab Injection products
A representative set of FDA-listed product records for Atezolizumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 840 mg/14 mL | Intravenous | Genentech, Inc. | BLA | View NDC → |
| 1200 mg/20 mL | Intravenous | Genentech, Inc. | BLA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Atezolizumab Injection NDCs →
Atezolizumab Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Atezolizumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Atezolizumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Atezolizumab Injection FDA approval history
How Atezolizumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Atezolizumab Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Atezolizumab recalls since July 2021.
✅No Atezolizumab recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1792776 1 dose form · 2 strengths
-
Dose form (SCDF) Injection RxCUI 1792779In current FDA listingsClinical drug / strength (SCD) 14 ML atezolizumab 60 MG/MLRxCUI 211969520 ML atezolizumab 60 MG/MLRxCUI 1792780
Look up RxCUI 1792776 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Atezolizumab Injection supply and shortage status
Whether Atezolizumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Atezolizumab Injection brand names
Atezolizumab Injection is sold under one brand name in the FDA directory — Tecentriq. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Atezolizumab Injection: manufacturers and labelers
One company lists Atezolizumab Injection products with the FDA. By number of product records, the largest are Genentech, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Atezolizumab Injection drug class (RxNorm)
Atezolizumab Injection belongs to the Programmed Death Receptor-1 Blocking Antibody class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Atezolizumab Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genentech, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →